<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04720781</url>
  </required_header>
  <id_info>
    <org_study_id>Revisiting</org_study_id>
    <nct_id>NCT04720781</nct_id>
  </id_info>
  <brief_title>The Need of Revisiting to an Outpatient Clinic After the Prescription of Vonoprazan or Esomeprazole</brief_title>
  <official_title>The Need of Revisiting to an Outpatient Clinic After the Prescription of Vonoprazan or Esomeprazole for 4weeks for Erosive Esophagitis Without Any Appointments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Showa Inan General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Showa Inan General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After vonoprazan (20mg/day) or esomeprazole (20mg/day) for 4weeks is prescribed for patients&#xD;
      with erosive esophagitis diagnosed by esophagogastroduodenoscopy, the number of patients who&#xD;
      will visit our outpatient clinic again due to some reasons without any appointments is&#xD;
      compared with vonoprazan group and esomeprazole.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Patients who have erosive esophagitis diagnosed by esophagogastroduodenoscopy is&#xD;
           enrolled.&#xD;
&#xD;
        2. Vonoprazan (20mg/day) or esomeprazole (20mg/day) is prescribed for 4weeks the patients&#xD;
           randomly without next appointments.&#xD;
&#xD;
        3. Some patients may visit our outpatient clinic again due to some reasons without any&#xD;
           appointments.&#xD;
&#xD;
        4. The number of the patients who revisit our outpatient clinic again is compared with&#xD;
           vonoprazan group and esomeprazole.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Anticipated">January 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 19, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of patients who revisit our outpatient clinic after the prescription without any appointments</measure>
    <time_frame>3 months</time_frame>
    <description>The need to revisit our outpatient clinic again without any appointments may show the patients' satisfaction or dissatisfaction after the prescription of vonoprazan or esomeprazole. The difference in the number between the two groups may show the difference in the effectiveness between the two medicines.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the main symptom with patients after/before medication when the patients revisit again</measure>
    <time_frame>3 months</time_frame>
    <description>The ratio of the degree of the main symptom after/before taking the medicine Good 0%- Bad 100%</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Questionnaire on satisfaction with taking the medicine at revisiting</measure>
    <time_frame>3months</time_frame>
    <description>The patient's satisfaction is assessed using visual analogue scale (Exellent 100% to very bad 0%).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>Vonoprazan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vonoprazan (20mg/day) is prescribed for patients with erosive esophagitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esomeprazole</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Esomeprazole (20mg/day) is prescribed for patients with erosive esophagitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vonoprazan</intervention_name>
    <description>Vonoprazan (20mg/day) is prescribed for 4 weeks.</description>
    <arm_group_label>Vonoprazan</arm_group_label>
    <other_name>Esomeprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>esomeprazole (20mg/day)</description>
    <arm_group_label>Esomeprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  outpatients belonging to American Society of Anesthesiologists class I or II&#xD;
&#xD;
          -  patients have erosive esophagitis diagnosed by esophagogastroduodenoscopy shortly&#xD;
             before the prescription&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other acid blockers are taken&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Akira Horiuchi, MD</last_name>
    <phone>81265822121</phone>
    <phone_ext>3012</phone_ext>
    <email>horiuchi.akira@sihp.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Showa Inan General hospital</name>
      <address>
        <city>Komagane</city>
        <state>Nagano</state>
        <zip>399-4191</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akira Horiuchi, M.D.</last_name>
      <phone>81265822121</phone>
      <phone_ext>3012</phone_ext>
      <email>horiuchi.akira@sihp.jp</email>
    </contact>
    <investigator>
      <last_name>Akira Horiuchi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 17, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Showa Inan General Hospital</investigator_affiliation>
    <investigator_full_name>Akira Horiuchi</investigator_full_name>
    <investigator_title>Chief of Digestive Disease Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

